# Extreme Networks Inc: financial statements, quarterly

EXTR · Nasdaq · CIK 1078271 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/extr.md) · [Financials](/companies/extr/financials.md) · [Filings](/companies/extr/filings.md) · [Insiders](/companies/extr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/extr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [296](/filings/0000950170-25-011087.md) | [211](/filings/0000950170-25-061827.md) | [257 d](/filings/0001193125-26-352872.md) | [269](/filings/0001193125-25-258554.md) | [279](/filings/0001193125-26-029334.md) | [285](/filings/0001193125-26-197200.md) | [307 d](/filings/0001193125-26-352872.md) | [310](/filings/0001193125-26-437803.md) | [318](/filings/0001193125-26-029334.md) | [317](/filings/0001193125-26-197200.md) | [339 d](/filings/0001193125-26-352872.md) | [341](/filings/0001193125-26-437803.md) |
| Cost of revenue | $m | [113](/filings/0000950170-25-011087.md) | [91.1](/filings/0000950170-25-061827.md) | [142 d](/filings/0001193125-26-352872.md) | [99.7](/filings/0001193125-25-258554.md) | [104](/filings/0001193125-26-029334.md) | [109](/filings/0001193125-26-197200.md) | [118 d](/filings/0001193125-26-352872.md) | [122](/filings/0001193125-26-437803.md) | [123](/filings/0001193125-26-029334.md) | [121](/filings/0001193125-26-197200.md) | [128 d](/filings/0001193125-26-352872.md) | [129](/filings/0001193125-26-437803.md) |
| Gross profit | $m | [183](/filings/0000950170-25-011087.md) | [120](/filings/0000950170-25-061827.md) | [115 d](/filings/0001193125-26-352872.md) | [170](/filings/0001193125-25-258554.md) | [175](/filings/0001193125-26-029334.md) | [175](/filings/0001193125-26-197200.md) | [189 d](/filings/0001193125-26-352872.md) | [188](/filings/0001193125-26-437803.md) | [195](/filings/0001193125-26-029334.md) | [196](/filings/0001193125-26-197200.md) | [210 d](/filings/0001193125-26-352872.md) | [212](/filings/0001193125-26-437803.md) |
| Research and development | $m | [52.8](/filings/0000950170-25-011087.md) | [54.5](/filings/0000950170-25-061827.md) | [46.6 d](/filings/0001193125-26-352872.md) | [54.5](/filings/0001193125-25-258554.md) | [54.9](/filings/0001193125-26-029334.md) | [55.7](/filings/0001193125-26-197200.md) | [56.5 d](/filings/0001193125-26-352872.md) | [57.8](/filings/0001193125-26-437803.md) | [57.5](/filings/0001193125-26-029334.md) | [59.2](/filings/0001193125-26-197200.md) | [59.4 d](/filings/0001193125-26-352872.md) | [57.8](/filings/0001193125-26-437803.md) |
| Operating income | $m | [10.3](/filings/0000950170-25-011087.md) | [(62.5)](/filings/0000950170-25-061827.md) | [(48.9) d](/filings/0001193125-26-352872.md) | [(4.7)](/filings/0001193125-25-258554.md) | [12.7](/filings/0001193125-26-029334.md) | [10.4](/filings/0001193125-26-197200.md) | [(1.4) d](/filings/0001193125-26-352872.md) | [11.3](/filings/0001193125-26-437803.md) | [13.0](/filings/0001193125-26-029334.md) | [17.3](/filings/0001193125-26-197200.md) | [21.1 d](/filings/0001193125-26-352872.md) | [23.1](/filings/0001193125-26-437803.md) |
| Interest expense | $m | [4.3](/filings/0000950170-25-011087.md) | [4.2](/filings/0000950170-25-061827.md) | [4.2 d](/filings/0001193125-26-352872.md) | [4.4](/filings/0001193125-25-258554.md) | [4.2](/filings/0001193125-26-029334.md) | [3.8](/filings/0001193125-26-197200.md) | [3.5 d](/filings/0001193125-26-352872.md) | [3.7](/filings/0001193125-26-437803.md) | [3.4](/filings/0001193125-26-029334.md) | [3.2](/filings/0001193125-26-197200.md) | [3.5 d](/filings/0001193125-26-352872.md) | [5.2](/filings/0001193125-26-437803.md) |
| Income tax | $m | [3.1](/filings/0000950170-25-011087.md) | [(0.6)](/filings/0000950170-25-061827.md) | [1.5 d](/filings/0001193125-26-352872.md) | [1.5](/filings/0001193125-25-258554.md) | [2.6](/filings/0001193125-26-029334.md) | [3.7](/filings/0001193125-26-197200.md) | [3.9 d](/filings/0001193125-26-352872.md) | [2.7](/filings/0001193125-26-437803.md) | [2.5](/filings/0001193125-26-029334.md) | [4.2](/filings/0001193125-26-197200.md) | [(0.1) d](/filings/0001193125-26-352872.md) | [2.5](/filings/0001193125-26-437803.md) |
| Net income | $m | [4.0](/filings/0000950170-25-011087.md) | [(64.4)](/filings/0000950170-25-061827.md) | [(54.2) d](/filings/0001193125-26-352872.md) | [(10.5)](/filings/0001193125-25-258554.md) | [7.4](/filings/0001193125-26-029334.md) | [3.5](/filings/0001193125-26-197200.md) | [(7.8) d](/filings/0001193125-26-352872.md) | [5.6](/filings/0001193125-26-437803.md) | [7.9](/filings/0001193125-26-029334.md) | [10.6](/filings/0001193125-26-197200.md) | [18.0 d](/filings/0001193125-26-352872.md) | [16.0](/filings/0001193125-26-437803.md) |
| Diluted EPS | $ per share | [0.03](/filings/0000950170-25-011087.md) | [(0.50)](/filings/0000950170-25-061827.md) | not reported | [(0.08)](/filings/0001193125-25-258554.md) | [0.06](/filings/0001193125-26-029334.md) | [0.03](/filings/0001193125-26-197200.md) | not reported | [0.04](/filings/0001193125-26-437803.md) | [0.06](/filings/0001193125-26-029334.md) | [0.08](/filings/0001193125-26-197200.md) | not reported | [0.12](/filings/0001193125-26-437803.md) |
| Basic EPS | $ per share | [0.03](/filings/0000950170-25-011087.md) | [(0.50)](/filings/0000950170-25-061827.md) | not reported | [(0.08)](/filings/0001193125-25-258554.md) | [0.06](/filings/0001193125-26-029334.md) | [0.03](/filings/0001193125-26-197200.md) | not reported | [0.04](/filings/0001193125-26-437803.md) | [0.06](/filings/0001193125-26-029334.md) | [0.08](/filings/0001193125-26-197200.md) | not reported | [0.12](/filings/0001193125-26-437803.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [221](/filings/0000950170-24-009819.md) | [151](/filings/0000950170-24-052140.md) | [157](/filings/0000950170-25-109742.md) | [160](/filings/0000950170-24-119570.md) | [170](/filings/0000950170-25-011087.md) | [185](/filings/0000950170-25-061827.md) | [232](/filings/0001193125-26-352872.md) | [209](/filings/0001193125-25-258554.md) | [220](/filings/0001193125-26-029334.md) | [210](/filings/0001193125-26-197200.md) | [212](/filings/0001193125-26-437803.md) | [245](/filings/0001193125-26-437803.md) |
| Current assets | $m | [558](/filings/0000950170-24-009819.md) | [506](/filings/0000950170-24-052140.md) | [467](/filings/0000950170-25-109742.md) | [477](/filings/0000950170-24-119570.md) | [495](/filings/0000950170-25-011087.md) | [477](/filings/0000950170-25-061827.md) | [535](/filings/0001193125-26-352872.md) | [526](/filings/0001193125-25-258554.md) | [536](/filings/0001193125-26-029334.md) | [542](/filings/0001193125-26-197200.md) | [550](/filings/0001193125-26-437803.md) | [671](/filings/0001193125-26-437803.md) |
| Total assets | $m | [1,143](/filings/0000950170-24-009819.md) | [1,085](/filings/0000950170-24-052140.md) | [1,043](/filings/0000950170-25-109742.md) | [1,057](/filings/0000950170-24-119570.md) | [1,081](/filings/0000950170-25-011087.md) | [1,073](/filings/0000950170-25-061827.md) | [1,153](/filings/0001193125-26-352872.md) | [1,153](/filings/0001193125-25-258554.md) | [1,169](/filings/0001193125-26-029334.md) | [1,170](/filings/0001193125-26-197200.md) | [1,178](/filings/0001193125-26-437803.md) | [1,302](/filings/0001193125-26-437803.md) |
| Current liabilities | $m | [549](/filings/0000950170-24-009819.md) | [528](/filings/0000950170-24-052140.md) | [518](/filings/0000950170-25-109742.md) | [526](/filings/0000950170-24-119570.md) | [534](/filings/0000950170-25-011087.md) | [512](/filings/0000950170-25-061827.md) | [588](/filings/0001193125-26-352872.md) | [577](/filings/0001193125-25-258554.md) | [565](/filings/0001193125-26-029334.md) | [593](/filings/0001193125-26-197200.md) | [593](/filings/0001193125-26-437803.md) | [659](/filings/0001193125-26-437803.md) |
| Long-term debt | $m | [183](/filings/0000950170-24-009819.md) | [181](/filings/0000950170-24-052140.md) | [178](/filings/0000950170-25-109742.md) | [174](/filings/0000950170-24-119570.md) | [171](/filings/0000950170-25-011087.md) | [167](/filings/0000950170-25-061827.md) | [164](/filings/0001193125-26-352872.md) | [159](/filings/0001193125-25-258554.md) | [154](/filings/0001193125-26-029334.md) | [149](/filings/0001193125-26-197200.md) | [144](/filings/0001193125-26-437803.md) | [200](/filings/0001193125-26-437803.md) |
| Current portion of debt | $m | [9.3](/filings/0000950170-24-009819.md) | [9.3](/filings/0000950170-24-052140.md) | [9.3](/filings/0000950170-25-109742.md) | [10.5](/filings/0000950170-24-119570.md) | [11.7](/filings/0000950170-25-011087.md) | [13.0](/filings/0000950170-25-061827.md) | [14.3](/filings/0001193125-26-352872.md) | [40.5](/filings/0001193125-25-258554.md) | [16.8](/filings/0001193125-26-029334.md) | [48.1](/filings/0001193125-26-197200.md) | [19.3](/filings/0001193125-26-437803.md) | [0.0](/filings/0001193125-26-437803.md) |
| Shareholders' equity | $m | [108](/filings/0000950170-25-061827.md) | [65.0](/filings/0000950170-25-061827.md) | [25.3](/filings/0001193125-26-352872.md) | [32.7](/filings/0001193125-26-029334.md) | [51.2](/filings/0001193125-26-197200.md) | [71.7](/filings/0001193125-26-197200.md) | [65.6](/filings/0001193125-26-437803.md) | [68.6](/filings/0001193125-26-437803.md) | [95.9](/filings/0001193125-26-197200.md) | [79.0](/filings/0001193125-26-197200.md) | [88.6](/filings/0001193125-26-437803.md) | [88.0](/filings/0001193125-26-437803.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [34.2 d](/filings/0000950170-25-011087.md) | [(69.9) d](/filings/0000950170-25-061827.md) | [15.5 d](/filings/0001193125-26-352872.md) | [18.6](/filings/0001193125-25-258554.md) | [21.5 d](/filings/0001193125-26-029334.md) | [30.0 d](/filings/0001193125-26-197200.md) | [81.9 d](/filings/0001193125-26-352872.md) | [(14.0)](/filings/0001193125-26-437803.md) | [50.1 d](/filings/0001193125-26-029334.md) | [14.2 d](/filings/0001193125-26-197200.md) | [72.8 d](/filings/0001193125-26-352872.md) | [45.4](/filings/0001193125-26-437803.md) |
| Capital expenditure | $m | [5.6 d](/filings/0000950170-25-011087.md) | [3.7 d](/filings/0000950170-25-061827.md) | [4.5 d](/filings/0001193125-26-352872.md) | [6.9](/filings/0001193125-25-258554.md) | [5.4](/filings/0001193125-26-029334.md) | [5.7](/filings/0001193125-26-197200.md) | [6.6 d](/filings/0001193125-26-352872.md) | [6.9](/filings/0001193125-26-437803.md) | [7.1](/filings/0001193125-26-029334.md) | [6.4](/filings/0001193125-26-197200.md) | [7.6 d](/filings/0001193125-26-352872.md) | [6.8](/filings/0001193125-26-437803.md) |
| Share repurchases | $m | [25.0 d](/filings/0000950170-25-011087.md) | [0.0 d](/filings/0000950170-25-061827.md) | [0.0 d](/filings/0001193125-26-352872.md) | not reported | not reported | not reported | [25.0 d](/filings/0001193125-26-352872.md) | [12.0](/filings/0001193125-26-437803.md) | [0.0 d](/filings/0001193125-26-029334.md) | [50.0 d](/filings/0001193125-26-197200.md) | [25.0 d](/filings/0001193125-26-352872.md) | [25.0](/filings/0001193125-26-437803.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [134](/filings/0000950170-24-009819.md) | [133](/filings/0000950170-24-052140.md) | [133](/filings/0000950170-24-119570.md) | [132](/filings/0000950170-25-011087.md) | [129](/filings/0000950170-25-061827.md) | [131](/filings/0001193125-25-258554.md) | [134](/filings/0001193125-26-029334.md) | [135](/filings/0001193125-26-197200.md) | [135](/filings/0001193125-26-437803.md) | [135](/filings/0001193125-26-029334.md) | [134](/filings/0001193125-26-197200.md) | [135](/filings/0001193125-26-437803.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 131,190,896 at 2026-10-23, from the cover of the [10-Q filed 2026-10-29](/filings/0001193125-26-437803.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 17:33 ET. No prices; not investment advice.